From The Motley Fool · Motley Fool Transcribing · · 2m
GSK Q3 2026 Earnings Report Highlights
GSK reports 5% sales growth with specialty medicines driving momentum in Q3 2026.
In brief
GSK reports 5% sales growth with specialty medicines driving momentum in Q3 2026. GSK's Q3 2026 earnings show 5% sales growth at constant exchange rates driven by specialty medicines, with core operating profit growing 5% and R&D investment up 22%. Originally reported by The Motley Fool.
Q3 2026 Performance
GSK reported third-quarter revenue of GBP 8.9 billion, growing 5% at constant exchange rates.
Specialty Medicines Growth
Specialty medicines revenue grew 15% at constant exchange rates, led by HIV and respiratory product performance.
Cabenuva Performance
Cabenuva sales grew 35% during the quarter, with 75% of U.S. switches originating from competitor products.
Exdensur Launch
Exdensur revenue reached GBP 27 million following its launch and availability of the J-code in July.
Shingrix Performance
Shingrix performance declined 2% at constant exchange rates due to destocking in China.
Trelegy Sales
Trelegy U.S. sales grew 8% as patients reached Medicare deductibles despite pricing pressures.
Meningitis Portfolio
Meningitis portfolio rose 12% at constant exchange rates supported by back-to-school season for Penmenvy.
Apretude Growth
Apretude growth rose 21% in the quarter, maintaining market share in HIV prevention segment.
Nucala Revenue
Nucala revenue increased 18% at constant exchange rates driven by successful launch in COPD indication.
Phase III Pipeline
18 phase III trial starts completed for 2026, including two new trials for influenza.
Jideytro Launch
Jideytro sales reached GBP 3 million, representing first contribution from ROS1 positive nonsmall cell lung cancer treatment.
Core EPS Growth
Core EPS grew 1% at constant exchange rates, impacted by increased interest costs and higher tax rate.
Full-Year Interest Expense
Full-year interest expense guidance of GBP 700 million to GBP 750 million, including GBP 160 million for Nuvalent acquisition.
Accelerate Growth Program
Accelerate Growth Program charges of GBP 0.3 billion in the quarter, with total 2026 charges expected up to GBP 1 billion.
Cash Flow from Operations
Cash flow from operations reached GBP 7.4 billion year to date, representing a GBP 1.1 billion increase over prior year.
Net Debt to Core EBITDA
Net debt to core EBITDA ratio remains at 1.8x, reflecting Nuvalent acquisition impact.
In short
GSK's Q3 2026 earnings show 5% sales growth at constant exchange rates driven by specialty medicines, with core operating profit growing 5% and R&D investment up 22%.
